Related Experiment Video
Updated: Jun 7, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
[Heart failure update 2010 and current ESC guidelines]
1Klinik III für Innere Medizin, Universität zu Köln, Kerpener Str. 62, 50937, Köln. uta.hoppe@uni-koeln.de
Abstract:
Chronic heart failure may be caused by systolic pump failure and/or impairment of diastolic filling of the ventricles. Standard pharmacotherapy of systolic heart failure includes an ACE inhibitor, betablocker, diuretics and in patients with severe symptoms a low-dose aldosterone antagonist. An AT(1) receptor blocker is indicated in those not tolerating ACE inhibitors. If patients remain in functional class NYHA III-IV despite optimal medication and have cardiac dyssynchrony, biventricular pacing may improve symptoms and prognosis. While evidence-based treatment significantly reduces morbidity and mortality in systolic heart failure, hardly any results of clinical trials are available for diastolic heart failure. Therefore, therapy in patients with diastolic heart failure remains symptomatic in most cases.
More Related Videos
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VII: Nursing Interventions
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations

